跳至主要内容
临床试验/CTRI/2026/02/103527
CTRI/2026/02/103527招募中3 期

Preclinical and Clinical Study To Evaluate The Safety and Efficacy of Bootha Chakkara Podi for Sooli Kanam (Childhood bronchial asthma) in children (6 -12 years of age) attending OPD of National Institute Of Siddha - An Open Clinical Trial

未提供1 个研究点 分布在 1 个国家目标入组 148 人开始时间: 2026年2月20日最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
148
试验地点
1

研究概览

简要总结

This study is a non-randomised, open-label clinical trial conducted at the Outpatient Department of the National Institute of Siddha to evaluate the efficacy and safety of Siddha formulations in the management of Sooli Kanam (childhood bronchial asthma). A total of 148 children aged 6–12 years diagnosed with Sooli Kanam are enrolled in the study. Participants are allocated into two treatment groups, with 74 participants receiving Bootha Chakkara Podi and 74 participants receiving Thaalisaathi Chooranam .The study drugs are administered orally for a period of 48 days twice a day. Participants are followed throughout the treatment period for assessment of efficacy and safety.Clinical symptoms are assessed  on Days 8, 15, 22, 29, 36, and 49. Pulmonary function is evaluated by spirometry, measuring Forced Expiratory Volume in one second (FEV1) and other pulmonary function parameters at baseline Day 1, Day 22, and Day 49. All observations are documented in the Case Report Form .The primary outcome measure is Percentage reduction  in FEV1 from baseline to the end of treatment. Secondary outcome measures is to compare the efficacy of Bootha chakkara podi and Thaalisaathi chooranam in improving clinical symptoms.Percentage reduction in the symptoms of  Childhood Bronchial Asthma  through Paediatric Asthma Severity Score(PASS) from baseline to the end of the treatment. The study aims to generate clinical evidence on the effectiveness and safety of Siddha medicines in childhood bronchial asthma.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
6.00 Year(s) 至 12.00 Year(s)(—)
性别
All

入选标准

  • Forced expiratory volume in 1s(FEV1) is between 60% AND 80%.
  • Peak Expiratory Flow Rate more than 50%[mild,moderate exacerbation].

排除标准

  • Forced expiratory volume in 1s(FEV1) is below 60 %.
  • Peak Expiratory Flow Rate less than 50%[severe exacerbation].

研究者

发起方
未提供
责任方
Principal Investigator
主要研究者

Dr S PRIYADHARSHINI

National institute of siddha

研究点 (1)

Loading locations...

相似试验